Purple Biotech Reports Second Half and Full-Year 2021 Financial Results
February 09, 2022 07:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Issues Letter to Shareholders
February 04, 2022 07:35 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance
October 22, 2021 06:00 ET
|
Purple Biotech Ltd.
Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy NT219, which Targets IRS, Shown to be Highly...
Purple Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results
March 02, 2021 07:00 ET
|
Purple Biotech Ltd.
Rehovot, Israel, March 02, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies...